类风湿关节炎生物制剂治疗中联合甲氨蝶呤可改善客观疾病活动度
这项前瞻性队列研究纳入330例类风湿关节炎患者,评估生物制剂联合甲氨蝶呤与单药治疗的差异。结果显示联合治疗使DAS28缓解 likelihood 提高55%,DAS28-ESR 略低(β=-0.42),但 RAPID3 无差异,支持继续联用甲氨蝶呤以改善客观结局。
要点
- 生物制剂联合甲氨蝶呤较单药治疗使 DAS28 缓解 likelihood 提高55%。
- 联合治疗降低 DAS28-ESR 水平(β=-0.42),主要归因于肿胀关节数减少。
- RAPID3 患者报告结局在联合与单药治疗间无显著差异。
核心结论
- 在常规诊疗的类风湿关节炎患者中,生物制剂联合甲氨蝶呤较生物制剂单药治疗可获得更好的客观疾病活动度控制,支持继续联用甲氨蝶呤。
研究设计与样本
- 前瞻性队列研究,纳入330例接受生物制剂或传统合成 DMARD 治疗的类风湿关节炎患者,平均随访10.7个月。
主要发现
- 联合治疗较单药治疗使 DAS28 缓解 likelihood 提高55%。
- 联合治疗组 DAS28-ESR 随时间略低(β=-0.42,95%CI -0.67 至 -0.17)。
- 联合治疗对 RAPID3 无显著影响(β=-0.58,95%CI -0.65 至 0.49)。
- DAS28-ESR 的改善完全由肿胀关节数降低所解释。
关键数值与推荐
- DAS28 缓解定义为 DAS28-ESR <2.6;RAPID3 缓解定义为 ≤3(范围0-30)。
临床怎么用
- 对接受生物制剂治疗的类风湿关节炎患者,应继续联用甲氨蝶呤以改善客观疾病活动度指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. METHODS: Patients with RA on treatment with either bDMARDs or conventional synthetic DMARDs were included in this prospective cohort study. The effect of (time-varying) combination therapy with bDMARD and MTX compared with bDMARD monotherapy was tested in longitudinal generalised estimating equation models using as outcomes: (1) the likelihood to be in remission according to the 28-joint Disease Activity Score (DAS28) erythrocyte sedimentation rate (ESR) (<2.6) and to the Routine Assessment of Patient Index Data 3 (RAPID3) (0-30; ≤3), a patient-reported outcome measure about RA symptoms; and (2) DAS28-ESR and RAPID3 as continuous variables. All models were adjusted for potential confounders: age, gender, drugs for comorbidities (yes/no), oral steroids (yes/no) and non-steroidal anti-inflammatory drug (yes/no). RESULTS: In total, 330 patients were included (mean (SD) follow-up; 10.7 (9.7) months). Compared with bDMARD monotherapy, MTX combination therapy was significantly associated with a 55% higher likelihood to be in DAS28 remission, but not RAPID3 remission, over time. Combination therapy resulted in slightly, but statistically significant, lower levels of DAS28-ESR over time (β=-0.42 (95% CI -0.67 to - 0.17)), but not RAPID3 (β=-0.58 (95% CI -0.65 to 0.49)). The effect on DAS28-ESR was entirely explained by lower swollen joint counts and was persistent after correction for confounders. CONCLUSION: These results give support to the policy that MTX should be continued in routine care patients with RA on biological therapy since this leads to better objective but not subjective clinical outcomes.
引用
- Boone NW, Sepriano A, van der Kuy PH, et al. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. RMD Open. 2019. PMID: 30740244. doi:10.1136/rmdopen-2018-000836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。